메뉴 건너뛰기
BJU International
Volumn 98, Issue 1, 2006, Pages 8-9
Radiommunotherapy and prostate cancer: A promising new therapy in the management of metastatic disease
Author keywords

Metastatic; Prostate cancer; Radioimmunotherapy; Treatment
Indexed keywords

GAMMA GLUTAMYL HYDROLASE; LANTHANIDE; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; UNCLASSIFIED DRUG; YTTRIUM 90;
EID: 33745075686     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06245.x     Document Type: Note
Times cited : (3)
References (10)
  • 1
    • 15944376260 scopus 로고    scopus 로고
    • Radioimmunotherapy of prostate cancer
    • Smith-Jones PM. Radioimmunotherapy of prostate cancer. Q J Nucl Med Mol Imaging 2004 48: 297 304
    • (2004) Q J Nucl Med Mol Imaging , vol.48 , pp. 297-304
    • Smith-Jones, P.M.1
  • 2
    • 2942580978 scopus 로고    scopus 로고
    • Targeted alpha-therapy for control of micrometastatic prostate cancer
    • Li Y Russell PJ Allen BJ. Targeted alpha-therapy for control of micrometastatic prostate cancer. Expert Rev Anticancer Ther 2004 4: 459 68
    • (2004) Expert Rev Anticancer Ther , vol.4 , pp. 459-68
    • Li, Y.1    Russell, P.J.2    Allen, B.J.3
  • 3
    • 9244224115 scopus 로고    scopus 로고
    • Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells
    • Press OW Shan D Howell-Clark J et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996 56: 2123 9
    • (1996) Cancer Res , vol.56 , pp. 2123-9
    • Press, O.W.1    Shan, D.2    Howell-Clark, J.3
  • 4
    • 23044469097 scopus 로고    scopus 로고
    • Radioimmunotherapy of prostate cancer: Does tumor size matter?
    • Scott AM. Radioimmunotherapy of prostate cancer: does tumor size matter? J Clin Oncol 2005 23: 4567 9
    • (2005) J Clin Oncol , vol.23 , pp. 4567-9
    • Scott, A.M.1
  • 5
    • 22044451179 scopus 로고    scopus 로고
    • Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
    • Bander NH Milowsky MI Nanus DM Kostakoglu L Vallabhajosula S Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005 23: 4591 601
    • (2005) J Clin Oncol , vol.23 , pp. 4591-601
    • Bander, N.H.1    Milowsky, M.I.2    Nanus, D.M.3    Kostakoglu, L.4    Vallabhajosula, S.5    Goldsmith, S.J.6
  • 6
    • 4344618391 scopus 로고    scopus 로고
    • Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer
    • Milowsky MI Nanus DM Kostakoglu L Vallabhajosula S Goldsmith SJ Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004 22: 2522 31
    • (2004) J Clin Oncol , vol.22 , pp. 2522-31
    • Milowsky, M.I.1    Nanus, D.M.2    Kostakoglu, L.3    Vallabhajosula, S.4    Goldsmith, S.J.5    Bander, N.H.6
  • 7
    • 0037083345 scopus 로고    scopus 로고
    • Rationales, evidence and design considerations for fractionated radioimmunotherapy
    • DeNardo GL Schlom J Buchsbaum DJ et al. Rationales, evidence and design considerations for fractionated radioimmunotherapy. Cancer 2002 94 ( Suppl. 4 1332 48
    • (2002) Cancer , vol.94 , Issue.4 SUPPL. , pp. 1332-48
    • Denardo, G.L.1    Schlom, J.2    Buchsbaum, D.J.3
  • 9
    • 27744595755 scopus 로고    scopus 로고
    • Radioimmunotherapy for non-Hodgkin's lymphoma
    • Rao AV Akabani G Rizzieri DA. Radioimmunotherapy for non-Hodgkin's lymphoma. Clin Med Res 2005 3: 157 65
    • (2005) Clin Med Res , vol.3 , pp. 157-65
    • Rao, A.V.1    Akabani, G.2    Rizzieri, D.A.3
  • 10
    • 23844507146 scopus 로고    scopus 로고
    • High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody
    • Richman CM Denardo SJ O'Donnell RT et al. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res 2005 11: 5920 7
    • (2005) Clin Cancer Res , vol.11 , pp. 5920-7
    • Richman, C.M.1    Denardo, S.J.2    O'Donnell, R.T.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.